Kempharm Piotroski F Score

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

This module uses fundamental data of Kempharm to approximate its Piotroski F score. Kempharm F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Kempharm. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Kempharm financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please see Kempharm Altman Z Score, Kempharm Correlation, Kempharm Valuation, as well as analyze Kempharm Alpha and Beta and Kempharm Hype Analysis.

Search Piotroski F Score 

Kempharm Issuance Repayment of Debt Securities is most likely to in the upcoming years. The last year's value of Issuance Repayment of Debt Securities was reported at 2.82 Million. Kempharm Tangible Assets Book Value per Share are most likely to decrease significantly in the upcoming years. The last year's value of Tangible Assets Book Value per Share was reported at 2.82
At this time, it appears that Kempharm's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
Piotroski F Score - Frail
Current Return On Assets
Change in Return on Assets
Cash Flow Return on Assets
Current Quality of Earnings (accrual)
Asset Turnover Growth
Current Ratio Change
Long Term Debt Over Assets Change
Higher Leverage
Change In Outstending Shares
Change in Gross Margin
No Change

Kempharm Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Kempharm is to make sure Kempharm is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Kempharm's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Kempharm's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares4.3 MM
Significantly Up
Slightly volatile
Weighted Average Shares Diluted4.3 MM
Significantly Up
Slightly volatile
Total Assets11.5 M11.2 M
Fairly Up
Total Liabilities82.9 M77.6 M
Notably Up
Slightly volatile
Current Assets8.6 M8.4 M
Fairly Up
Current Liabilities8.4 M7.5 M
Significantly Up
Slightly volatile
Total Debt70.5 M70.4 M
Slightly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Asset Turnover1.261.218
Sufficiently Up
Slightly volatile

Kempharm F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Kempharm's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Kempharm in a much-optimized way.

About Kempharm Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

Kempharm Book Value per Share is most likely to increase significantly in the upcoming years. The last year's value of Book Value per Share was reported at -16.68

Kempharm Current Valuation Drivers

We derive many important indicators used in calculating different scores of Kempharm from analyzing Kempharm's financial statements. These drivers represent accounts that assess Kempharm's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kempharm's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Average Assets99 M64.11 M30.53 M14.07 M10.91 M11.19 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(10.85 M)(37.32 M)(50.8 M)(19.38 M)(7.74 M)(8.35 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(10.85 M)(37.32 M)(50.8 M)(19.38 M)(7.74 M)(8.35 M)
Earnings before Tax(16.53 M)(43.43 M)(56.59 M)(24.54 M)(12.79 M)(13.8 M)
Average Equity(9.91 M)(44.71 M)(81.28 M)(75.36 M)(65.07 M)(70.21 M)
Enterprise Value112.15 M142.95 M135.37 M85.21 M114.02 M118.94 M
Free Cash Flow(30.41 M)(33.28 M)(54.22 M)(23.76 M)(1.97 M)(2.13 M)
Invested Capital152.37 M122.46 M77.67 M81.05 M69.7 M76.98 M
Invested Capital Average147.93 M137.1 M92.2 M76.47 M19.55 M20.07 M
Market Capitalization43.21 M59.36 M47.09 M12.6 M50.78 M61.81 M
Tangible Asset Value84.89 M52.46 M26.75 M10.51 M11.21 M11.5 M
Working Capital67.72 M34.39 M11.72 M1.54 M846 K868.26 K

About Kempharm Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kempharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kempharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kempharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Risk-Return Analysis Now


Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kempharm Altman Z Score, Kempharm Correlation, Kempharm Valuation, as well as analyze Kempharm Alpha and Beta and Kempharm Hype Analysis. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Equity Valuation
Check real value of public entities based on technical and fundamental data
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.